Overview of included RRMS phase-3 trials (n = 13).

Patient and healthy control characteristics at baseline.

Johan Mellergård (307388)
Anders Tisell (307389)
Olof Dahlqvist Leinhard (307390)
Ida Blystad (307391)
Anne-Marie Landtblom (307392)
Kaj Blennow (58615)
Bob Olsson (307393)
Charlotte Dahle (307394)
Jan Ernerudh (45215)
Peter Lundberg (307397)
Magnus Vrethem (307399)

February 2013

aMedian number of years from first symptoms of MS to inclusion.bTreatment within 4 months ...

Change of annualized relapse rates of MS phase-3 placebo cohorts over time.

Jan-Patrick Stellmann (116774)
Anneke Neuhaus (116775)
Lena Herich (116776)
Sven Schippling (116777)
Matthias Roeckel (116778)
Martin Daumer (20109)
Roland Martin (56671)
Christoph Heesen (116779)

November 2012

n = 13. Circle size corresponds to weighting by patient numbers of each cohort. R2 is the proport...

Results of the multiple variables Cox’s regression analysis.

Viviana Nociti (5306822)
Massimo Santoro (141869)
Davide Quaranta (444021)
Francesco Antonio Losavio (5883881)
Chiara De Fino (5883884)
Rocco Giordano (5883887)
Nicole Palomba (5883890)
Paolo Maria Rossini (55412)
Franca Rosa Guerini (335425)
Mario Clerici (34848)
Domenico Caputo (335431)
Massimiliano Mirabella (84288)

October 2018

ARR: annualized relapse rate; ARR-MRI: annualized MRI relapse rate; HR: hazard ratio; SE: standard e...

Number of RRMS patients who initiated a DMD since 2 years before baseline, treatment exposure time, number of relapses, number of patients experiencing a relapse and annualized relapse rate (ARR).

Giulio Disanto (125817)
Pascal Benkert (2586778)
Johannes Lorscheider (2586763)
Stefanie Mueller (375818)
Jochen Vehoff (2586775)
Chiara Zecca (2586769)
Simon Ramseier (2586760)
Lutz Achtnichts (614650)
Oliver Findling (517065)
Krassen Nedeltchev (2586766)
Ernst-Wilhelm Radue (513045)
Till Sprenger (513046)
Christoph Stippich (513044)
Tobias Derfuss (204827)
Jean-François Louvion (2586781)
Christian P. Kamm (517062)
Heinrich P. Mattle (517070)
Christoph Lotter (2586784)
Renaud Du Pasquier (2157907)
Myriam Schluep (295565)
Caroline Pot (2586754)
Patrice H. Lalive (233901)
Özgür Yaldizli (2586772)
Claudio Gobbi (2586757)
Ludwig Kappos (253872)
Jens Kuhle (346208)

March 2016

Only DMDs used in at least 10 SMSC patients and with at least 1 year of mean follow-up are shown....

Placebo cohorts of RRMS trials 1996–2013 (n = 21).

Jan-Patrick Stellmann (116774)
Klarissa Hanja Stürner (690574)
Kim Lea Young (690575)
Susanne Siemonsen (664349)
Tim Friede (690576)
Christoph Heesen (116779)

February 2015

RRMS = Relapsing-remitting Multiple Sclerosis, Pub.Year = Year of Publication, N = patients in pl...

Individual patient cohort – final Poisson and logistic regression models.

Jan-Patrick Stellmann (116774)
Anneke Neuhaus (116775)
Lena Herich (116776)
Sven Schippling (116777)
Matthias Roeckel (116778)
Martin Daumer (20109)
Roland Martin (56671)
Christoph Heesen (116779)

November 2012

ARR = Annualized relapse rate over 2 years, Logistic regression: Outcome was coded as 1 for at ...

Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data

Stellmann, J P
Neuhaus, A
Herich, L
Schippling, S
Roeckel, M
Daumer, M
Martin, R
Heesen, C

November 2012

BACKGROUND: Annualized relapse rates (ARR) in the placebo cohorts of phase-3 randomized controlled t...

Placebo Cohorts in Phase-3 MS Treatment Trials – Predictors for On-Trial Disease Activity 1990-2010 Based on a Meta-Analysis and Individual Case Data

Jan-Patrick Stellmann (116774)
Anneke Neuhaus (116775)
Lena Herich (116776)
Sven Schippling (116777)
Matthias Roeckel (116778)
Martin Daumer (20109)
Roland Martin (56671)
Christoph Heesen (116779)

November 2012

<div><h3>Background</h3>Annualized relapse rates (ARR) in the placebo cohorts of phase-3 randomiz...

Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data.

Jan-Patrick Stellmann
Anneke Neuhaus
Lena Herich
Sven Schippling
Matthias Roeckel
Martin Daumer
Roland Martin
Christoph Heesen

BACKGROUND: Annualized relapse rates (ARR) in the placebo cohorts of phase-3 randomized controlled t...

RRs and 95% CIs for (A) 2-year relapse risk and (B) 5-year OS, according to a subgroup analysis of CBF-AML.

Wenlan Chen (846226)
Hui Xie (195238)
Hongxiang Wang (433625)
Li Chen (5749)
Yi Sun (118759)
Zhichao Chen (846227)
Qiubai Li (306378)

January 2016

The number of included studies, number of patients in the included studies, and percentage of pat...

Association of vitamin D status and relapses (yes/no) during three year follow-up in RRMS-onset patients—per age categories (n = 123 per quartile) at baseline.

Anne-Hilde Muris (2824910)
Joost Smolders (235367)
Linda Rolf (2824916)
Lieke J. J. Klinkenberg (486859)
Noreen van der Linden (2824913)
Steven Meex (2824907)
Jan Damoiseaux (235391)
Raymond Hupperts (235385)

June 2016

Association of vitamin D status and relapses (yes/no) during three year follow-up in RRMS-onset p...

Analysis on the annualized relapse rate reduction at 2 years reported for patients with relapsing remitting multiple sclerosis included in the randomized clinical trials of Natalizumab or Fingolimod.

Georgios Tsivgoulis (665231)
Aristeidis H. Katsanos (700374)
Dimitris Mavridis (3184881)
Nikolaos Grigoriadis (261798)
Efthymios Dardiotis (3184878)
Ioannis Heliopoulos (700375)
Panagiotis Papathanasopoulos (789573)
Theodoros Karapanayiotides (3184875)
Constantinos Kilidireas (700376)
Georgios M. Hadjigeorgiou (342829)
Konstantinos Voumvourakis (700377)

September 2016

Analysis on the annualized relapse rate reduction at 2 years reported for patients with relapsing...

Association of vitamin D status and relapses (yes/no) during three year follow-up in RRMS-onset patients—Model 1: main variables.

Anne-Hilde Muris (2824910)
Joost Smolders (235367)
Linda Rolf (2824916)
Lieke J. J. Klinkenberg (486859)
Noreen van der Linden (2824913)
Steven Meex (2824907)
Jan Damoiseaux (235391)
Raymond Hupperts (235385)

June 2016

Association of vitamin D status and relapses (yes/no) during three year follow-up in RRMS-onset p...

Observed and predicted relapse rates in arms of three phase 3 trials of fluoroquinolone-containing regimens.

Robert S. Wallis (286546)
Thomas Peppard (731793)
David Hermann (731794)

April 2015

Evaluable subjects are those who at end-of-treatment have not met other unsatisfactory endpoints....

Predictors for relapses – Association of variables with outcomes within a mixed-effect model.

Jan-Patrick Stellmann (116774)
Anneke Neuhaus (116775)
Lena Herich (116776)
Sven Schippling (116777)
Matthias Roeckel (116778)
Martin Daumer (20109)
Roland Martin (56671)
Christoph Heesen (116779)

November 2012

Taû2 is the estimate of residual heterogeneity. A higher reduction of taû2 within the mixed-effec...

Patient and healthy control characteristics at baseline.

Johan Mellergård (307388)
Anders Tisell (307389)
Olof Dahlqvist Leinhard (307390)
Ida Blystad (307391)
Anne-Marie Landtblom (307392)
Kaj Blennow (58615)
Bob Olsson (307393)
Charlotte Dahle (307394)
Jan Ernerudh (45215)
Peter Lundberg (307397)
Magnus Vrethem (307399)

February 2013

aMedian number of years from first symptoms of MS to inclusion.bTreatment within 4 months ...

Change of annualized relapse rates of MS phase-3 placebo cohorts over time.

Jan-Patrick Stellmann (116774)
Anneke Neuhaus (116775)
Lena Herich (116776)
Sven Schippling (116777)
Matthias Roeckel (116778)
Martin Daumer (20109)
Roland Martin (56671)
Christoph Heesen (116779)

November 2012

n = 13. Circle size corresponds to weighting by patient numbers of each cohort. R2 is the proport...

Results of the multiple variables Cox’s regression analysis.

Viviana Nociti (5306822)
Massimo Santoro (141869)
Davide Quaranta (444021)
Francesco Antonio Losavio (5883881)
Chiara De Fino (5883884)
Rocco Giordano (5883887)
Nicole Palomba (5883890)
Paolo Maria Rossini (55412)
Franca Rosa Guerini (335425)
Mario Clerici (34848)
Domenico Caputo (335431)
Massimiliano Mirabella (84288)

October 2018

ARR: annualized relapse rate; ARR-MRI: annualized MRI relapse rate; HR: hazard ratio; SE: standard e...

Number of RRMS patients who initiated a DMD since 2 years before baseline, treatment exposure time, number of relapses, number of patients experiencing a relapse and annualized relapse rate (ARR).

Giulio Disanto (125817)
Pascal Benkert (2586778)
Johannes Lorscheider (2586763)
Stefanie Mueller (375818)
Jochen Vehoff (2586775)
Chiara Zecca (2586769)
Simon Ramseier (2586760)
Lutz Achtnichts (614650)
Oliver Findling (517065)
Krassen Nedeltchev (2586766)
Ernst-Wilhelm Radue (513045)
Till Sprenger (513046)
Christoph Stippich (513044)
Tobias Derfuss (204827)
Jean-François Louvion (2586781)
Christian P. Kamm (517062)
Heinrich P. Mattle (517070)
Christoph Lotter (2586784)
Renaud Du Pasquier (2157907)
Myriam Schluep (295565)
Caroline Pot (2586754)
Patrice H. Lalive (233901)
Özgür Yaldizli (2586772)
Claudio Gobbi (2586757)
Ludwig Kappos (253872)
Jens Kuhle (346208)

March 2016

Only DMDs used in at least 10 SMSC patients and with at least 1 year of mean follow-up are shown....

Placebo cohorts of RRMS trials 1996–2013 (n = 21).

Jan-Patrick Stellmann (116774)
Klarissa Hanja Stürner (690574)
Kim Lea Young (690575)
Susanne Siemonsen (664349)
Tim Friede (690576)
Christoph Heesen (116779)

February 2015

RRMS = Relapsing-remitting Multiple Sclerosis, Pub.Year = Year of Publication, N = patients in pl...

Individual patient cohort – final Poisson and logistic regression models.

Jan-Patrick Stellmann (116774)
Anneke Neuhaus (116775)
Lena Herich (116776)
Sven Schippling (116777)
Matthias Roeckel (116778)
Martin Daumer (20109)
Roland Martin (56671)
Christoph Heesen (116779)

November 2012

ARR = Annualized relapse rate over 2 years, Logistic regression: Outcome was coded as 1 for at ...

Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data

Stellmann, J P
Neuhaus, A
Herich, L
Schippling, S
Roeckel, M
Daumer, M
Martin, R
Heesen, C

November 2012

BACKGROUND: Annualized relapse rates (ARR) in the placebo cohorts of phase-3 randomized controlled t...

Placebo Cohorts in Phase-3 MS Treatment Trials – Predictors for On-Trial Disease Activity 1990-2010 Based on a Meta-Analysis and Individual Case Data

Jan-Patrick Stellmann (116774)
Anneke Neuhaus (116775)
Lena Herich (116776)
Sven Schippling (116777)
Matthias Roeckel (116778)
Martin Daumer (20109)
Roland Martin (56671)
Christoph Heesen (116779)

November 2012

<div><h3>Background</h3>Annualized relapse rates (ARR) in the placebo cohorts of phase-3 randomiz...

Placebo cohorts in phase-3 MS treatment trials - predictors for on-trial disease activity 1990-2010 based on a meta-analysis and individual case data.

Jan-Patrick Stellmann
Anneke Neuhaus
Lena Herich
Sven Schippling
Matthias Roeckel
Martin Daumer
Roland Martin
Christoph Heesen

BACKGROUND: Annualized relapse rates (ARR) in the placebo cohorts of phase-3 randomized controlled t...

RRs and 95% CIs for (A) 2-year relapse risk and (B) 5-year OS, according to a subgroup analysis of CBF-AML.

Wenlan Chen (846226)
Hui Xie (195238)
Hongxiang Wang (433625)
Li Chen (5749)
Yi Sun (118759)
Zhichao Chen (846227)
Qiubai Li (306378)

January 2016

The number of included studies, number of patients in the included studies, and percentage of pat...

Association of vitamin D status and relapses (yes/no) during three year follow-up in RRMS-onset patients—per age categories (n = 123 per quartile) at baseline.

Anne-Hilde Muris (2824910)
Joost Smolders (235367)
Linda Rolf (2824916)
Lieke J. J. Klinkenberg (486859)
Noreen van der Linden (2824913)
Steven Meex (2824907)
Jan Damoiseaux (235391)
Raymond Hupperts (235385)

June 2016

Association of vitamin D status and relapses (yes/no) during three year follow-up in RRMS-onset p...

Analysis on the annualized relapse rate reduction at 2 years reported for patients with relapsing remitting multiple sclerosis included in the randomized clinical trials of Natalizumab or Fingolimod.

Georgios Tsivgoulis (665231)
Aristeidis H. Katsanos (700374)
Dimitris Mavridis (3184881)
Nikolaos Grigoriadis (261798)
Efthymios Dardiotis (3184878)
Ioannis Heliopoulos (700375)
Panagiotis Papathanasopoulos (789573)
Theodoros Karapanayiotides (3184875)
Constantinos Kilidireas (700376)
Georgios M. Hadjigeorgiou (342829)
Konstantinos Voumvourakis (700377)

September 2016

Analysis on the annualized relapse rate reduction at 2 years reported for patients with relapsing...

Association of vitamin D status and relapses (yes/no) during three year follow-up in RRMS-onset patients—Model 1: main variables.

Anne-Hilde Muris (2824910)
Joost Smolders (235367)
Linda Rolf (2824916)
Lieke J. J. Klinkenberg (486859)
Noreen van der Linden (2824913)
Steven Meex (2824907)
Jan Damoiseaux (235391)
Raymond Hupperts (235385)

June 2016

Association of vitamin D status and relapses (yes/no) during three year follow-up in RRMS-onset p...

Observed and predicted relapse rates in arms of three phase 3 trials of fluoroquinolone-containing regimens.

Robert S. Wallis (286546)
Thomas Peppard (731793)
David Hermann (731794)

April 2015

Evaluable subjects are those who at end-of-treatment have not met other unsatisfactory endpoints....

Predictors for relapses – Association of variables with outcomes within a mixed-effect model.

Jan-Patrick Stellmann (116774)
Anneke Neuhaus (116775)
Lena Herich (116776)
Sven Schippling (116777)
Matthias Roeckel (116778)
Martin Daumer (20109)
Roland Martin (56671)
Christoph Heesen (116779)

November 2012

Taû2 is the estimate of residual heterogeneity. A higher reduction of taû2 within the mixed-effec...

Patient and healthy control characteristics at baseline.

Johan Mellergård (307388)
Anders Tisell (307389)
Olof Dahlqvist Leinhard (307390)
Ida Blystad (307391)
Anne-Marie Landtblom (307392)
Kaj Blennow (58615)
Bob Olsson (307393)
Charlotte Dahle (307394)
Jan Ernerudh (45215)
Peter Lundberg (307397)
Magnus Vrethem (307399)

February 2013

aMedian number of years from first symptoms of MS to inclusion.bTreatment within 4 months ...

Change of annualized relapse rates of MS phase-3 placebo cohorts over time.

Jan-Patrick Stellmann (116774)
Anneke Neuhaus (116775)
Lena Herich (116776)
Sven Schippling (116777)
Matthias Roeckel (116778)
Martin Daumer (20109)
Roland Martin (56671)
Christoph Heesen (116779)

November 2012

n = 13. Circle size corresponds to weighting by patient numbers of each cohort. R2 is the proport...

Results of the multiple variables Cox’s regression analysis.

Viviana Nociti (5306822)
Massimo Santoro (141869)
Davide Quaranta (444021)
Francesco Antonio Losavio (5883881)
Chiara De Fino (5883884)
Rocco Giordano (5883887)
Nicole Palomba (5883890)
Paolo Maria Rossini (55412)
Franca Rosa Guerini (335425)
Mario Clerici (34848)
Domenico Caputo (335431)
Massimiliano Mirabella (84288)

October 2018

ARR: annualized relapse rate; ARR-MRI: annualized MRI relapse rate; HR: hazard ratio; SE: standard e...

Overview of included RRMS phase-3 trials (n = 13).

Abstract

Extracted data

Overview of included RRMS phase-3 trials (n = 13).

Abstract

Extracted data

Related items

Related items